T
TRIMTECH Therapeutics
Biotech & Life Sciences · Cambridge, United Kingdom · Founded 2023
Developing small molecule degraders targeting protein aggregates for neurodegenerative and inflammatory disorders MoreLess
TrimTech Therapeutics focuses on creating orally active small molecule degraders that target protein aggregates, addressing significant medical needs in neurodegenerative and inflammatory disorders. The company leverages pioneering research into TRIM21, a ubiquitin ligase, to develop a differentiated portfolio of potent and highly specific degraders. These degraders selectively remove toxic proteins while preserving the non-aggregated forms essential for healthy cellular function. TrimTech operates in the pharmaceutical and biotechnology sectors, serving clients in the healthcare industry who require advanced therapeutic solutions for intractable CNS and inflammatory conditions. The business model centers on research and development, with revenue generated through partnerships, licensing agreements, and potential commercialization of its therapeutic products. The team comprises world-renowned scientists and experienced executives with a proven track record in developing novel therapeutics. Keywords: TRIM21, ubiquitin ligase, protein aggregates, neurodegenerative, inflammatory, small molecule, degraders, CNS disorders, biotechnology, therapeutics.
Company overview
TRIMTECH Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2023
- Headquarters
- Cambridge, United Kingdom
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 56.7
Valuation & funding
TRIMTECH Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Jun 2026 | $14M | $56M | MP Healthcare Venture Management · Johnson & Johnson Innovation · Johnson & Johnson Innovative Medicine · Dementia Discovery Fund | ↗ |
| EARLY VCOther financing | Mar 2026 | $11M | $152M | Undisclosed | ↗ |
| SEEDOther financing | Mar 2025 | $31M | $124M | MP Healthcare Venture Management · Pfizer · Eli Lilly · Start Codon | ↗ |
| SPINOUTOther financing | Dec 2023 | $0 | — | MRC Laboratory of Molecular Biology · University of Cambridge · KU Leuven | — |
Growth signals
TRIMTECH Therapeutics website traffic
Latest recorded traffic for TRIMTECH Therapeutics is 2.2K monthly website visits, up 249.2% over the last three months. TRIMTECH Therapeutics's team grew 0% over the past year.
Comparisons
TRIMTECH Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
TRIMTECH Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
17 investors on TRIMTECH Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where TRIMTECH Therapeutics has talent and traffic
team presence
In the news
Latest news about TRIMTECH Therapeutics
Recent press, funding announcements, and product moves mentioning TRIMTECH Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about TRIMTECH Therapeutics
An AI-synthesized read of the highest-engagement posts about TRIMTECH Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TRIMTECH Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.